The futility study--Progress over the last decade
Copyright © 2015 Elsevier Inc. All rights reserved..
We review the futility clinical trial design (also known as the non-superiority design) with respect to its emergence and methodologic developments over the last decade, especially in regard to its application to clinical trials for neurological disorders. We discuss the design's strengths as a programmatic screening device to weed out unpromising new treatments, its limitations and pitfalls, and a recent critique of the logic of the method.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Contemporary clinical trials - 45(2015), Pt A vom: 30. Nov., Seite 69-75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levin, Bruce [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Futility design |
|---|
| Anmerkungen: |
Date Completed 29.08.2016 Date Revised 21.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cct.2015.06.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM250432277 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250432277 | ||
| 003 | DE-627 | ||
| 005 | 20231224155731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cct.2015.06.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0834.xml |
| 035 | |a (DE-627)NLM250432277 | ||
| 035 | |a (NLM)26123873 | ||
| 035 | |a (PII)S1551-7144(15)30029-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levin, Bruce |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The futility study--Progress over the last decade |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2016 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 Elsevier Inc. All rights reserved. | ||
| 520 | |a We review the futility clinical trial design (also known as the non-superiority design) with respect to its emergence and methodologic developments over the last decade, especially in regard to its application to clinical trials for neurological disorders. We discuss the design's strengths as a programmatic screening device to weed out unpromising new treatments, its limitations and pitfalls, and a recent critique of the logic of the method | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Futility design | |
| 650 | 4 | |a Non-superiority design | |
| 650 | 4 | |a Phase II trials | |
| 650 | 4 | |a Screening program | |
| 773 | 0 | 8 | |i Enthalten in |t Contemporary clinical trials |d 2005 |g 45(2015), Pt A vom: 30. Nov., Seite 69-75 |w (DE-627)NLM154869031 |x 1559-2030 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2015 |g number:Pt A |g day:30 |g month:11 |g pages:69-75 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cct.2015.06.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2015 |e Pt A |b 30 |c 11 |h 69-75 | ||